
  
    
      
        Background_NNP
        Sequence_NNP homology_NN between_IN the_DT serotonin_NN type_NN 3_CD receptor_NN
        (_( 5_CD -_: HT_NNP 
        3_CD R_NN )_) ,_, the_DT nicotinic_JJ acetylcholine_NN
        receptor_NN (_( nAChR_NN )_) ,_, the_DT GABA_NNP 
        A_DT receptor_NN and_CC the_DT glycine_NN receptor_NN
        suggests_VBZ a_DT large_JJ amount_NN of_IN structural_JJ similarity_NN within_IN
        this_DT superfamily_RB of_IN ligand_NN gated_JJ ion_NN channels_NNS [_NN 1_CD 2_CD 3_CD ]_NN ._.
        This_DT presumed_VBN structural_JJ homology_NN can_MD be_VB used_VBN to_TO guide_VB site_NN
        directed_VBD mutagenesis_NNS studies_NNS of_IN particular_JJ receptor_NN
        subtypes_NNS ._. On_IN a_DT gross_JJ level_NN ,_, all_DT members_NNS of_IN this_DT superfamily_RB
        assemble_VB as_IN pentameric_JJ receptors_NNS [_NN 4_CD ]_NN ._. In_IN some_DT cases_NNS ,_,
        receptors_NNS can_MD be_VB assembled_VBN from_IN a_DT single_JJ subunit_NN (_( 5_CD -_: HT_NNP 
        3_CD A_DT R_NN and_CC nicotinic_JJ α_NN 7_CD receptors_NNS )_) [_NN 1_CD 5_CD 6_CD
        7_CD 8_CD ]_NN ._. In_IN other_JJ cases_NNS ,_, at_IN least_JJS two_CD different_JJ subunits_NNS are_VBP
        required_VBN [_NN 2_CD 4_CD 9_CD ]_NN ._. The_DT ligand_NN binding_JJ site_NN is_VBZ thought_VBN to_TO
        be_VB formed_VBN at_IN the_DT junction_NN between_IN two_CD subunits_NNS [_NN 2_CD 4_CD ]_NN
        ._.
        Based_VBN on_IN data_NNS obtained_VBN from_IN affinity_NN labeling_VBG and_CC site_NN
        directed_VBD mutagenesis_NNS studies_NNS ,_, several_JJ regions_NNS of_IN the_DT
        nicotinic_JJ acetylcholine_NN receptor_NN have_VBP been_VBN implicated_VBN in_IN
        ligand_NN binding_JJ [_NN 10_CD ]_NN ._. Six_CD essential_JJ loops_NNS appear_VBP to_TO
        contribute_VB to_TO the_DT binding_JJ site_NN with_IN the_DT position_NN of_IN each_DT
        loop_NN differing_VBG slightly_RB depending_VBG on_IN whether_IN the_DT receptor_NN
        is_VBZ heteromeric_JJ or_CC homomeric_JJ [_NN 4_CD ]_NN ._. For_IN homomeric_JJ receptors_NNS
        such_JJ as_IN the_DT α_NN 7_CD nAChR_NN ,_, the_DT loops_NNS are_VBP identified_VBN as_IN A_DT ,_, B_NNP ,_, C_NNP ,_,
        D_NNP ,_, E_NNP and_CC F_NN [_NN 4_CD 11_CD ]_NN ._. The_DT amino_JJ acids_NNS that_WDT interact_NN with_IN
        ligands_NNS presumably_RB extend_VBP into_IN the_DT binding_JJ site_NN from_IN these_DT
        loops_NNS ._. Subunits_NNP are_VBP composed_VBN of_IN 2_CD faces_VBZ (_( +_NN and_CC -_: )_) with_IN the_DT
        +_NN face_NN of_IN one_CD subunit_NN forming_VBG one_CD side_NN of_IN the_DT binding_JJ site_NN
        and_CC the_DT -_: face_NN of_IN another_DT subunit_NN forming_VBG the_DT complimentary_JJ
        side_NN ._. Some_DT binding_JJ loops_NNS (_( A_DT ,_, B_NNP and_CC C_NNP )_) are_VBP present_JJ on_IN the_DT -_:
        face_NN while_IN the_DT remaining_VBG loops_NNS (_( D_NNP and_CC E_NNP )_) are_VBP present_JJ on_IN the_DT
        +_NN face_NN ._. [_NN 4_CD ]_NN ._. The_DT individual_JJ amino_JJ acids_NNS that_WDT form_NN
        binding_JJ interactions_NNS with_IN the_DT functional_JJ groups_NNS present_JJ on_IN
        a_DT ligand_NN are_NN likely_JJ to_TO differ_VB for_IN each_DT receptor_NN subtype_NN ,_,
        reflecting_VBG the_DT specificity_NN of_IN a_DT particular_JJ binding_JJ site_NN ,_,
        however_RB ,_, the_DT overall_JJ structure_NN of_IN the_DT binding_JJ domain_NN may_MD be_VB
        similar_JJ even_RB for_IN binding_JJ sites_NNS with_IN different_JJ ligand_NN
        specificities_NNS ._. Identification_NNP of_IN ligand_NN specificity_NN
        requires_VBZ identification_NN of_IN both_DT the_DT location_NN or_CC structure_NN
        of_IN individual_JJ binding_JJ site_NN loops_NNS and_CC the_DT amino_JJ acids_NNS
        present_JJ in_IN a_DT particular_JJ receptor_NN subtype_NN ._.
        The_DT purpose_NN of_IN this_DT study_NN is_VBZ to_TO extend_VB the_DT information_NN
        available_JJ from_IN other_JJ members_NNS of_IN this_DT receptor_NN family_NN to_TO the_DT
        5_CD -_: HT_NNP 
        3_CD R_NN ._. Sequence_NNP homology_NN and_CC a_DT presumed_VBN
        structural_JJ similarity_NN to_TO other_JJ ligand_NN gated_JJ ion_NN channels_NNS
        suggests_VBZ that_IN the_DT E_NNP loop_NN region_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD A_DT R_NN forms_NNS part_NN of_IN the_DT ligand_NN binding_JJ
        domain_NN for_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS ._. This_DT region_NN extends_VBZ from_IN
        Y_NNP 140_CD to_TO K_NNP 153_CD and_CC is_VBZ shown_VBN in_IN Table_NNP 1_CD ._. The_DT homologous_RB
        sequences_NNS of_IN other_JJ representative_NN members_NNS of_IN this_DT family_NN
        are_VBP also_RB shown_VBN ._. In_IN the_DT center_NN of_IN this_DT region_NN is_VBZ a_DT critical_JJ
        glycine_NN residue_NN that_WDT is_VBZ thought_VBN to_TO play_VB a_DT role_NN in_IN
        establishing_VBG a_DT hairpin_NN loop_NN [_NN 12_CD ]_NN ._. Recent_JJ x-ray_JJ
        crystallographic_JJ data_NNS obtained_VBN from_IN an_DT ACh_NNP binding_JJ protein_NN
        (_( AChBP_NNP )_) shows_VBZ a_DT loop_NN structure_NN in_IN this_DT region_NN resulting_VBG
        from_IN a_DT 3_CD residue_NN turn_NN containing_VBG a_DT glycine_NN homologous_RB to_TO
        G_NNP 147_CD of_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ._. On_IN either_DT side_NN of_IN this_DT putative_JJ
        turn_NN region_NN are_VBP residues_NNS that_WDT have_VBP been_VBN identified_VBN as_IN
        important_JJ to_TO receptor_NN binding_JJ [_NN 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._.
        The_DT formation_NN of_IN this_DT loop_NN structure_NN brings_VBZ amino_JJ acids_NNS on_IN
        either_DT side_NN of_IN glycine_NN into_IN close_JJ proximity_NN and_CC may_MD form_VB a_DT
        binding_JJ pocket_NN that_WDT will_MD accommodate_VB one_CD or_CC more_RBR functional_JJ
        groups_NNS ._. In_IN order_NN to_TO identify_VB the_DT interaction_NN of_IN amino_JJ acids_NNS
        in_IN this_DT binding_JJ loop_NN with_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS ,_, we_PRP have_VBP constructed_VBN alanine_NN
        mutations_NNS of_IN residues_NNS throughout_IN this_DT region_NN and_CC evaluated_VBD
        the_DT alteration_NN in_IN binding_JJ affinity_NN of_IN 5_CD different_JJ classes_NNS
        of_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS (_( Figure_NN 1_LS )_) ._. Our_PRP$ data_NNS
        identifies_VBZ 3_CD tyrosine_NN residues_NNS that_WDT appear_VBP to_TO interact_NN
        selectively_RB with_IN each_DT structural_JJ class_NN and_CC supports_VBZ the_DT
        existence_NN of_IN a_DT loop_NN structure_NN in_IN this_DT region_NN of_IN the_DT
        receptor_NN ._.
      
      
        Results_NNS
        All_DT mutant_JJ receptors_NNS were_VBD tested_VBN for_IN their_PRP$ ability_NN to_TO
        bind_NN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN antagonist_NN [_NN 3_CD H_NNP ]_NN granisetron_NN ._. Table_NNP
        2_CD shows_VBZ the_DT K_NNP 
        d_SYM values_NNS for_IN wildtype_NN mouse_NN 5_CD -_: HT_NNP 
        3_CD AS_NNP Rs_NNP and_CC the_DT 13_CD alanine_NN mutations_NNS we_PRP
        evaluated_VBD ._. [_NN 3_CD H_NNP ]_NN granisetron_NN is_VBZ a_DT potent_JJ antagonist_NN of_IN the_DT
        wt_NN 5_CD -_: HT_NNP 
        3_CD R_NN (_( K_NNP 
        d_SYM =_SYM 0_CD ._. 98_CD ±_NN 0_CD ._. 12_CD nM_NN )_) ._. This_DT value_NN agrees_VBZ
        with_IN published_VBN data_NNS for_IN this_DT compound_NN [_NN 19_CD 20_CD ]_NN ._. B_NNP 
        max_NN values_NNS range_VBP from_IN the_DT 5_CD ._. 5_CD pmoles_NNS /_NN mg_NN
        protein_NN observed_VBD for_IN E_NNP 148_CD A_DT to_TO 0_CD ._. 30_CD pmoles_NNS /_NN mg_NN protein_NN for_IN
        the_DT K_NNP 153_CD A_DT mutation_NN ,_, indicating_VBG some_DT variability_NN in_IN
        expression_NN of_IN the_DT different_JJ receptors_NNS ._. In_IN general_JJ ,_, however_RB ,_,
        receptor_NN expression_NN was_VBD similar_JJ to_TO that_DT reported_VBN by_IN other_JJ
        laboratories_NNS [_NN 1_CD 20_CD 21_CD 22_CD ]_NN ._. No_DT detectable_JJ binding_JJ was_VBD
        observed_VBN for_IN G_NNP 147_CD A_DT and_CC V_NNP 149_CD A_DT mutant_JJ receptors_NNS ._. For_IN all_DT
        other_JJ mutants_NNS ,_, decreases_NNS in_IN binding_JJ affinity_NN (_( increased_VBN K_NNP 
        d_SYM )_) were_VBD observed_VBN although_IN the_DT magnitude_NN
        of_IN the_DT change_NN was_VBD less_JJR than_IN 10_CD fold_VB in_IN all_DT cases_NNS ._. A_DT bar_NN
        graph_NN showing_VBG the_DT change_NN in_IN K_NNP 
        d_SYM value_NN resulting_VBG from_IN each_DT alanine_NN
        mutation_NN is_VBZ shown_VBN in_IN Figure_NN 2_CD A_DT ._. The_DT largest_JJS decreases_NNS in_IN
        binding_JJ affinity_NN were_VBD observed_VBN for_IN Y_NNP 142_CD A_DT (_( 4_CD ._. 6_CD fold_VB ,_, Figure_NN
        3_LS )_) ,_, E_NNP 148_CD A_DT (_( 5_CD ._. 3_LS fold_VB )_) and_CC Q_NNP 150_CD A_DT -_: K_NNP 153_CD A_DT (_( 6_CD -_: 8_CD fold_VB )_) ._.
        Inhibition_NNP binding_JJ assays_NNS were_VBD also_RB conducted_VBN ._. Four_CD test_NN
        compounds_NNS with_IN structures_NNS representative_NN of_IN the_DT major_JJ
        classes_NNS of_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS were_VBD chosen_VBN :_: serotonin_NN
        (_( 5_CD -_: HT_NNP ,_, the_DT endogenous_JJ agonist_NN )_) ,_, 
        m_NN -_: chlorophenylbiguanide_NN (_( 
        m_NN CPBG_NNP ,_, agonist_NN )_) ,_, 
        d_SYM -_: tubocurarine_NN (_( 
        d_SYM -_: tc_NN ,_, antagonist_NN )_) and_CC lerisetron_NN
        (_( antagonist_NN )_) ._. The_DT K_NNP 
        i_NNP values_NNS for_IN inhibition_NN of_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN binding_VBG by_IN all_DT four_CD compounds_NNS are_VBP shown_VBN in_IN
        Table_NNP 3_CD ._. Little_NNP change_NN in_IN K_NNP 
        i_NNP value_NN was_VBD observed_VBN for_IN the_DT majority_NN of_IN
        mutations_NNS ._. The_DT values_NNS highlighted_VBN in_IN bold_JJ in_IN Table_NNP
        3_CD represent_VB the_DT K_NNP 
        i_NNP values_NNS for_IN inhibition_NN of_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN binding_JJ on_IN mutant_JJ receptors_NNS that_WDT increased_VBD
        over_IN 10_CD fold_VB compared_VBN to_TO the_DT K_NNP 
        i_NNP obtained_VBD for_IN wildtype_NN receptors_NNS ._. The_DT
        bar_NN chart_NN in_IN Figure_NN 2_CD Billustrates_NNP the_DT changes_NNS in_IN K_NNP 
        i_NNP resulting_VBG from_IN each_DT mutation_NN on_IN the_DT
        test_NN compounds_NNS ._. Ratios_NNP of_IN K_NNP 
        i_NNP are_VBP shown_VBN as_IN positive_JJ for_IN increases_NNS in_IN
        K_NNP 
        i_NNP on_IN mutant_JJ receptors_NNS versus_CC wildtype_NN
        and_CC negative_JJ for_IN decreases_NNS ._. A_DT positive_JJ change_NN thus_RB
        corresponds_NNS to_TO a_DT decrease_NN in_IN binding_JJ affinity_NN for_IN the_DT
        compound_NN as_IN a_DT result_NN of_IN the_DT mutation_NN ._. Large_JJ decreases_NNS in_IN
        binding_JJ affinity_NN were_VBD observed_VBN for_IN select_VB compounds_NNS only_RB on_IN
        the_DT Y_NNP 140_CD A_DT ,_, Y_NNP 142_CD A_DT and_CC Y_NNP 152_CD A_DT mutations_NNS ._.
        A_DT more_RBR detailed_JJ analysis_NN of_IN the_DT competition_NN binding_JJ data_NNS
        obtained_VBN for_IN the_DT Y_NNP 140_CD A_DT ,_, Y_NNP 142_CD A_DT and_CC Y_NNP 152_CD A_DT mutations_NNS is_VBZ shown_VBN
        in_IN Figure_NN 4_CD ._. For_IN 5_CD -_: HT_NNP ,_, the_DT Y_NNP 142_CD A_DT mutation_NN produced_VBD a_DT 110_CD
        fold_VB increase_NN in_IN K_NNP 
        i_NNP and_CC Y_NNP 152_CD A_DT produced_VBD a_DT 24_CD fold_VB increase_NN ._.
        No_DT change_NN in_IN K_NNP 
        i_NNP was_VBD observed_VBN for_IN the_DT Y_NNP 140_CD A_DT mutation_NN
        (_( Figure_NN 4_CD A_DT )_) ._. The_DT 5_CD -_: HT_NNP 
        3_CD R_NN agonist_NN 
        m_NN CPBG_NNP showed_VBD a_DT similar_JJ profile_NN for_IN
        the_DT changes_NNS in_IN K_NNP 
        i_NNP values_NNS resulting_VBG from_IN mutations_NNS of_IN the_DT
        three_CD tyrosines_NNS (_( Figure_NN 4_CD B_NNP )_) ._. As_IN was_VBD observed_VBN for_IN 5_CD -_: HT_NNP ,_, the_DT
        Y_NNP 142_CD A_DT mutation_NN produced_VBD a_DT large_JJ increase_NN in_IN K_NNP 
        i_NNP (_( 160_CD fold_VB )_) while_IN the_DT Y_NNP 14_CD 0_CD A_DT and_CC Y_NNP 152_CD A_DT
        mutations_NNS produced_VBN only_RB 7_CD and_CC 24_CD fold_VB changes_NNS
        respectively_RB ._.
        The_DT K_NNP 
        i_NNP value_NN for_IN 
        d_SYM -_: tc_NN inhibition_NN of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN
        binding_JJ was_VBD altered_VBN only_RB slightly_RB by_IN the_DT Y_NNP 142_CD A_DT or_CC Y_NNP 152_CD A_DT
        mutations_NNS (_( 6_CD ._. 5_LS fold_VB and_CC 10_CD fold_VB changes_NNS respectively_RB )_) ._. The_DT
        Y_NNP 140_CD A_DT mutation_NN ,_, however_RB ,_, produced_VBD a_DT 50_CD fold_VB increase_NN in_IN the_DT
        K_NNP 
        i_NNP compared_VBD to_TO wildtype_NN receptors_NNS (_( Figure_NN
        4_CD C_NNP )_) ._.
        The_DT K_NNP 
        i_NNP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN binding_JJ was_VBD increased_VBD 160_CD fold_VB by_IN the_DT Y_NNP 142_CD A_DT
        mutation_NN and_CC 190_CD fold_VB by_IN the_DT Y_NNP 152_CD A_DT mutation_NN ._. Only_RB a_DT 4_CD ._. 6_CD
        fold_VB change_NN in_IN K_NNP 
        i_NNP resulted_VBD from_IN the_DT Y_NNP 140_CD A_DT mutation_NN ._.
        Lerisetron_NNP was_VBD the_DT only_JJ compound_NN for_IN which_WDT a_DT large_JJ increase_NN
        in_IN the_DT K_NNP 
        i_NNP was_VBD observed_VBN on_IN the_DT Y_NNP 152_CD A_DT mutation_NN
        (_( Figure_NN 4_CD D_NNP )_) ._. This_DT mutation_NN produced_VBN smaller_JJR changes_NNS in_IN K_NNP 
        i_NNP for_IN 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP (_( 24_CD fold_VB for_IN both_DT )_) and_CC only_RB a_DT
        10_CD fold_VB change_NN for_IN 
        d_SYM -_: tc_NN ._.
        In_IN whole_JJ cell_NN patch_NN clamp_NN studies_NNS ,_, 5_CD -_: HT_NNP perfusion_NN of_IN
        cells_NNS transfected_JJ with_IN Y_NNP 140_CD A_DT and_CC Y_NNP 142_CD A_DT cDNA_NN produced_VBD no_DT
        responses_NNS at_IN 5_CD -_: HT_NNP concentrations_NNS of_IN up_IN to_TO 1_CD mM_NN although_IN
        specific_JJ binding_VBG to_TO these_DT receptors_NNS was_VBD identified_VBN in_IN
        receptor_NN binding_JJ studies_NNS ._. Unlike_IN Y_NNP 140_CD A_DT and_CC Y_NNP 142_CD A_DT ,_, Y_NNP 152_CD A_DT
        receptors_NNS responded_VBD to_TO application_NN of_IN 5_CD -_: HT_NNP ._. Due_JJ to_TO the_DT low_JJ
        potency_NN of_IN 5_CD -_: HT_NNP on_IN these_DT receptors_NNS ,_, only_RB a_DT portion_NN of_IN the_DT
        concentration_NN response_NN curve_NN could_MD be_VB determined_VBN (_( up_IN to_TO 1_CD
        mM_NN )_) ._. The_DT EC_NNP 
        50_CD value_NN was_VBD estimated_VBN as_IN greater_JJR than_IN
        370_CD μM_NN (_( Figure_NN 5_LS )_) ._. This_DT value_NN shows_VBZ a_DT greater_JJR than_IN 140_CD fold_VB
        increase_NN in_IN EC_NNP 
        50_CD compared_VBN to_TO wildtype_NN receptors_NNS ;_: a_DT
        larger_JJR change_NN than_IN was_VBD observed_VBN for_IN the_DT K_NNP 
        i_NNP (_( 24_CD fold_VB )_) ._. The_DT most_RBS dramatic_JJ change_NN
        observed_VBD for_IN whole_JJ cell_NN currents_NNS was_VBD an_DT alteration_NN in_IN the_DT
        kinetics_NNS of_IN the_DT response_NN elicited_JJ by_IN application_NN of_IN 5_CD -_: HT_NNP ._.
        Y_NNP 152_CD A_DT mutant_JJ receptors_NNS displayed_VBD much_RB slower_JJR rise_NN times_NNS
        compared_VBN to_TO wildtype_NN receptors_NNS at_IN all_DT concentrations_NNS
        tested_VBN ._. Peak_NNP wt_NN responses_NNS were_VBD typically_RB obtained_VBN in_IN less_JJR
        than_IN 80_CD ms_NNS while_IN Y_NNP 152_CD A_DT responses_NNS required_VBD several_JJ seconds_NNS
        to_TO plateau_NN ._. Desensitization_NNP kinetics_NNS were_VBD also_RB altered_VBN ._.
        While_IN wt_NN receptors_NNS desensitized_JJ rapidly_RB ,_, mutant_JJ receptors_NNS
        showed_VBD no_DT desensitization_NN during_IN the_DT 8_CD s_VBZ perfusion_NN
        time_NN ._.
      
      
        Discussion_NNP
        The_DT putative_JJ E-_NNP loop_NN region_NN of_IN the_DT LGIC_NNP family_NN of_IN
        receptors_NNS is_VBZ homologous_RB to_TO residues_NNS Y_NNP 140_CD through_IN K_NNP 153_CD in_IN
        the_DT 5_CD -_: HT_NNP 
        3_CD R_NN [_NN 4_CD 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._.
        Structure-function_NNP studies_NNS of_IN this_DT region_NN have_VBP been_VBN
        conducted_VBN in_IN several_JJ other_JJ members_NNS of_IN this_DT family_NN of_IN
        receptors_NNS including_VBG GABA_NNP 
        A_DT and_CC nAChR_NN subtypes_NNS ._. In_IN each_DT case_NN ,_,
        residues_NNS have_VBP been_VBN identified_VBN that_WDT alter_VBP either_DT the_DT binding_JJ
        of_IN selective_JJ ligands_NNS or_CC receptor_NN function_NN [_NN 4_CD 11_CD 12_CD 13_CD 14_CD
        15_CD 16_CD 17_CD 18_CD ]_NN ._. In_IN order_NN to_TO determine_VB if_IN this_DT loop_NN also_RB
        contains_VBZ residues_NNS critical_JJ to_TO the_DT structure_NN or_CC function_NN of_IN
        the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ,_, we_PRP have_VBP constructed_VBN alanine_NN
        mutations_NNS of_IN amino_JJ acids_NNS throughout_IN the_DT homologous_RB region_NN
        of_IN the_DT mouse_NN 5_CD -_: HT_NNP 
        3_CD AS_NNP R_NNP and_CC investigated_VBD the_DT affects_VBZ on_IN
        binding_JJ of_IN 5_CD different_JJ structural_JJ classes_NNS of_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS ._. We_PRP have_VBP identified_VBN three_CD
        tyrosine_NN residues_NNS that_WDT appear_VBP to_TO play_VB a_DT role_NN in_IN binding_JJ of_IN
        selective_JJ ligands_NNS to_TO this_DT receptor_NN ._. In_IN addition_NN ,_, our_PRP$ data_NNS
        support_VBP the_DT existence_NN of_IN a_DT loop_NN structure_NN in_IN this_DT region_NN as_IN
        has_VBZ been_VBN hypothesized_VBN for_IN the_DT nAChR_NN and_CC identified_VBN in_IN a_DT
        homologous_RB AChBP_NNP [_NN 12_CD 23_CD 24_CD ]_NN ._.
        Representative_NNP members_NNS of_IN 5_CD major_JJ structural_JJ classes_NNS of_IN
        5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS were_VBD tested_VBN on_IN all_DT mutants_NNS
        (_( Figure_NN 1_LS )_) ._. These_DT ligands_NNS include_VBP the_DT antagonists_NNS [_NN
        3_CD H_NNP ]_NN granisetron_NN ,_, 
        d_SYM -_: tc_NN and_CC lerisetron_NN ,_, and_CC the_DT
        agonists_NNS 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP ._. Most_JJS of_IN the_DT mutations_NNS tested_VBN
        produced_VBN only_RB minor_JJ changes_NNS in_IN binding_JJ affinity_NN for_IN these_DT
        ligands_NNS ._. Large_JJ changes_NNS in_IN binding_JJ are_VBP only_RB apparent_JJ on_IN
        Y_NNP 140_CD A_DT ,_, Y_NNP 142_CD A_DT and_CC Y_NNP 152_CD A_DT receptors_NNS for_IN select_VB ligands_NNS ._. The_DT
        resulting_VBG effects_NNS of_IN individual_JJ mutations_NNS are_VBP specific_JJ to_TO
        particular_JJ structural_JJ classes_NNS of_IN ligands_NNS ._. The_DT Y_NNP 140_CD A_DT
        mutation_NN altered_VBD the_DT K_NNP 
        i_NNP for_IN 
        d_SYM -_: tc_NN inhibition_NN ,_, but_CC did_VBD not_RB alter_VB
        the_DT K_NNP 
        i_NNP obtained_VBD for_IN any_DT other_JJ compound_NN
        tested_VBD ,_, while_IN Y_NNP 142_CD A_DT altered_VBD the_DT K_NNP 
        i_NNP for_IN 
        m_NN CPBG_NNP ,_, 5_CD -_: HT_NNP and_CC lerisetron_NN but_CC had_VBD
        little_JJ if_IN any_DT effect_NN on_IN inhibition_NN by_IN 
        d_SYM -_: tc_NN ._. These_DT data_NNS indicate_VBP the_DT highly_RB
        specific_JJ nature_NN of_IN the_DT effects_NNS introduced_VBN by_IN the_DT alanine_NN
        mutations_NNS and_CC appear_VB to_TO reflect_VB specific_JJ changes_NNS in_IN
        ligand_NN /_NN receptor_NN interaction_NN ._.
        Binding_NNP of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN is_VBZ altered_VBN only_RB slightly_RB by_IN
        the_DT alanine_NN mutations_NNS introduced_VBN in_IN this_DT study_NN (_( <_NN 10_CD
        fold_VB )_) ._. This_DT result_NN indicates_VBZ the_DT lack_NN of_IN involvement_NN of_IN
        amino_JJ acids_NNS in_IN this_DT binding_JJ loop_NN in_IN the_DT binding_JJ of_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN ._. It_PRP is_VBZ apparent_JJ ,_, however_RB ,_, that_DT [_NN
        3_CD H_NNP ]_NN granisetron_NN does_VBZ occupy_VB the_DT same_JJ binding_JJ cleft_NN as_IN other_JJ
        5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS as_IN evidenced_VBN by_IN the_DT ability_NN
        of_IN 5_CD -_: HT_NNP ,_, 
        m_NN CPBG_NNP ,_, 
        d_SYM -_: tc_NN and_CC lerisetron_NN to_TO displace_VB it_PRP
        from_IN the_DT binding_JJ site_NN ._. The_DT lack_NN of_IN any_DT large_JJ change_NN in_IN
        binding_JJ of_IN granisetron_NN supports_VBZ our_PRP$ contention_NN that_IN there_EX
        is_VBZ little_RB global_JJ structural_JJ perturbation_NN of_IN the_DT binding_JJ
        site_NN resulting_VBG from_IN the_DT introduction_NN of_IN each_DT individual_JJ
        alanine_NN mutation_NN ._.
        The_DT K_NNP 
        i_NNP for_IN inhibition_NN of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN
        binding_JJ by_IN 5_CD -_: HT_NNP was_VBD increased_VBD 110_CD fold_VB by_IN the_DT Y_NNP 142_CD A_DT
        mutation_NN ._. A_DT similar_JJ increase_NN was_VBD also_RB observed_VBN for_IN 
        m_NN CPBG_NNP (_( 160_CD fold_VB )_) ._. In_IN contrast_NN ,_, the_DT
        Y_NNP 140_CD A_DT and_CC Y_NNP 152_CD A_DT mutations_NNS produced_VBN relatively_RB small_JJ changes_NNS
        in_IN the_DT K_NNP 
        i_NNP ._. Since_IN both_DT compounds_NNS are_VBP 5_CD -_: HT_NNP 
        3_CD R_NN agonists_NNS ,_, they_PRP are_VBP likely_JJ to_TO share_VB
        the_DT same_JJ binding_JJ interactions_NNS ._. One_CD of_IN these_DT interactions_NNS
        appears_VBZ to_TO be_VB with_IN Y_NNP 142_CD ._. Other_JJ studies_NNS have_VBP also_RB identified_VBN
        binding_JJ site_NN interactions_NNS for_IN agonists_NNS ._. R_NN 91_CD ,_, E_NNP 106_CD ,_, F_NN 107_CD ,_,
        W_NNP 183_CD and_CC several_JJ residues_NNS adjacent_JJ to_TO the_DT M_NNP 1_CD region_NN have_VBP
        all_DT been_VBN demonstrated_VBN to_TO alter_VB the_DT action_NN of_IN 5_CD -_: HT_NNP and_CC /_NN or_CC 
        m_NN CPBG_NNP [_NN 20_CD 21_CD 25_CD 26_CD ]_NN ._. Within_IN the_DT
        crystal_NN structure_NN of_IN the_DT AChBP_NNP ,_, homologous_RB residues_NNS are_VBP
        located_VBN in_IN the_DT apparent_JJ binding_JJ site_NN [_NN 24_CD ]_NN ._. The_DT effects_NNS
        of_IN agonist_NN on_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN are_VBP mediated_JJ by_IN their_PRP$ interaction_NN
        with_IN these_DT binding_JJ site_NN residues_NNS ,_, resulting_VBG in_IN stable_JJ
        receptor_NN conformations_NNS ,_, including_VBG the_DT channel_NN open_JJ state_NN ._.
        Identification_NNP of_IN interacting_VBG amino_JJ acids_NNS and_CC their_PRP$
        location_NN in_IN the_DT tertiary_JJ structure_NN of_IN the_DT receptor_NN may_MD
        provide_VB clues_NNS to_TO the_DT mechanism_NN of_IN channel_NN opening_NN ._. For_IN
        example_NN ,_, amino_JJ acids_NNS homologous_RB to_TO Y_NNP 142_CD and_CC W_NNP 183_CD (_( R_NN 104_CD and_CC
        W_NNP 143_CD respectively_RB )_) are_VBP in_IN close_JJ proximity_NN in_IN the_DT AChBP_NNP ,_,
        although_IN on_IN complementary_JJ faces_NNS of_IN the_DT receptor_NN subunits_NNS [_NN
        24_CD ]_NN ._. Spier_NNP 
        et_CC ._. al_NN ._. have_VBP suggested_VBN that_IN W_NNP 183_CD may_MD
        be_VB involved_VBN in_IN a_DT cation-π_JJ interaction_NN with_IN the_DT amino_JJ group_NN
        of_IN 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP [_NN 26_CD ]_NN ._. If_IN W_NNP 183_CD and_CC Y_NNP 142_CD are_VBP
        located_VBN near_IN each_DT other_JJ but_CC on_IN opposite_JJ faces_NNS of_IN the_DT
        binding_JJ site_NN in_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ,_, then_RB they_PRP could_MD potentially_RB act_VB in_IN
        concert_NN to_TO help_VB stabilize_VB a_DT conformation_NN of_IN the_DT receptor_NN
        leading_VBG to_TO channel_VB opening_NN ._.
        
        d_SYM -_: Tubocurarine_NNP inhibition_NN was_VBD
        uniquely_RB altered_VBN by_IN the_DT Y_NNP 140_CD A_DT mutation_NN ._. An_DT increase_NN in_IN K_NNP 
        i_NNP of_IN 50_CD fold_VB was_VBD observed_VBN for_IN 
        d_SYM -_: tc_NN on_IN this_DT mutant_JJ ._. Little_RB if_IN any_DT
        change_NN resulted_VBD for_IN any_DT other_JJ mutation_NN ._. Thus_RB ,_, while_IN 
        d_SYM -_: tc_NN may_MD form_VB an_DT interaction_NN with_IN
        the_DT receptor_NN at_IN this_DT binding_JJ loop_NN ,_, it_PRP appears_VBZ to_TO interact_NN
        with_IN Y_NNP 140_CD rather_RB than_IN Y_NNP 142_CD or_CC Y_NNP 152_CD ._. This_DT difference_NN in_IN
        binding_JJ site_NN interactions_NNS of_IN the_DT antagonist_NN 
        d_SYM -_: tc_NN and_CC the_DT agonists_NNS 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP could_MD be_VB the_DT result_NN of_IN a_DT
        slightly_RB different_JJ positioning_NN of_IN 
        d_SYM -_: tc_NN in_IN the_DT binding_JJ site_NN ._. The_DT
        antagonists_NNS 
        d_SYM -_: tc_NN and_CC [_NN 3_CD H_NNP ]_NN granisetron_NN also_RB
        interact_NN differently_RB with_IN this_DT region_NN since_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN binding_JJ was_VBD not_RB altered_VBN by_IN mutations_NNS at_IN any_DT
        of_IN the_DT amino_JJ acids_NNS tested_VBN ._. While_IN the_DT binding_JJ of_IN 
        d_SYM -_: tc_NN appears_VBZ to_TO involve_VB some_DT
        interaction_NN with_IN this_DT binding_JJ loop_NN ,_, the_DT binding_JJ of_IN [_NN
        3_CD H_NNP ]_NN granisetron_NN does_VBZ not_RB ._. Previous_JJ studies_NNS have_VBP indicated_VBN a_DT
        point_NN of_IN overlap_VB between_IN [_NN 3_CD H_NNP ]_NN granisetron_NN and_CC 
        d_SYM -_: tc_NN at_IN W_NNP 89_CD of_IN the_DT 5_CD -_: HT_NNP 
        3_CD AS_NNP R_NNP ._. [_NN 20_CD ]_NN ._. These_DT studies_NNS indicate_VBP
        that_IN the_DT binding_JJ regions_NNS for_IN these_DT antagonists_NNS are_VBP
        partially_RB overlapping_VBG at_IN W_NNP 89_CD but_CC not_RB at_IN Y_NNP 140_CD ._. In_IN addition_NN
        to_TO Y_NNP 140_CD and_CC W_NNP 89_CD ,_, 
        d_SYM -_: tc_NN has_VBZ also_RB been_VBN observed_VBN to_TO
        interact_NN with_IN D_NNP 206_CD and_CC several_JJ other_JJ residues_NNS in_IN loop_NN C_NNP [_NN
        27_CD ]_NN ._. The_DT 
        d_SYM -_: tc_NN binding_JJ site_NN appears_VBZ to_TO involve_VB
        interaction_NN with_IN at_IN least_JJS three_CD different_JJ binding_JJ loops_NNS (_( A_DT ,_,
        E_NNP and_CC C_NNP )_) although_IN additional_JJ interacting_VBG amino_JJ acids_NNS may_MD be_VB
        found_VBN ._. Data_NNP obtained_VBD for_IN 
        d_SYM -_: tc_NN is_VBZ particularly_RB valuable_JJ due_NN to_TO
        the_DT rigid_JJ nature_NN of_IN this_DT molecule_NN ._. Determination_NNP of_IN
        interacting_VBG functional_JJ groups_NNS and_CC their_PRP$ relationship_NN to_TO
        individual_JJ amino_JJ acids_NNS could_MD enable_VB 
        d_SYM -_: tc_NN to_TO be_VB used_VBN as_IN a_DT molecular_JJ ruler_NN
        to_TO determine_VB relative_JJ positions_NNS of_IN these_DT amino_JJ acids_NNS ._.
        Lerisetron_NNP inhibition_NN of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN binding_JJ to_TO
        mutant_JJ receptors_NNS was_VBD also_RB investigated_VBN ._. Lerisetron_NNP is_VBZ a_DT
        potent_JJ 5_CD -_: HT_NNP 
        3_CD R_NN antagonist_NN first_RB synthesized_JJ by_IN
        Orales_NNP 
        et_CC ._. al_NN ._. [_NN 28_CD ]_NN ._. As_IN was_VBD observed_VBN for_IN
        5_CD -_: HT_NNP 
        3_CD R_NN agonists_NNS ,_, lerisetron_NN binding_JJ was_VBD
        altered_VBN by_IN the_DT Y_NNP 142_CD A_DT mutation_NN ._. This_DT mutation_NN produced_VBD an_DT
        increase_NN in_IN the_DT K_NNP 
        i_NNP of_IN 160_CD fold_VB compared_VBN to_TO wildtype_NN
        receptors_NNS ._. This_DT increase_NN in_IN K_NNP 
        i_NNP indicates_VBZ an_DT important_JJ interaction_NN of_IN
        lerisetron_NN with_IN Y_NNP 142_CD and_CC a_DT similarity_NN between_IN the_DT binding_JJ
        location_NN of_IN lerisetron_NN ,_, 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP ._. Lerisetron_NNP is_VBZ the_DT only_JJ
        antagonist_NN tested_VBN that_IN shares_VBZ a_DT binding_JJ site_NN interaction_NN in_IN
        this_DT region_NN with_IN agonists_NNS ._. In_IN contrast_NN to_TO 5_CD -_: HT_NNP and_CC 
        m_NN CPBG_NNP ,_, however_RB ,_, lerisetron_NN also_RB
        interacts_NNS with_IN Y_NNP 152_CD as_IN indicated_VBN by_IN the_DT 190_CD fold_VB increase_NN
        in_IN K_NNP 
        i_NNP on_IN Y_NNP 152_CD A_DT mutant_JJ receptors_NNS ._. Since_IN
        neither_DT 
        d_SYM -_: tc_NN nor_CC [_NN 3_CD H_NNP ]_NN granisetron_NN interacts_NNS
        with_IN Y_NNP 142_CD or_CC Y_NNP 152_CD ,_, there_EX appears_VBZ to_TO be_VB a_DT difference_NN between_IN
        the_DT interactions_NNS formed_VBN by_IN these_DT antagonists_NNS compared_VBN to_TO
        lerisetron_NN ._. The_DT binding_JJ sites_NNS of_IN the_DT three_CD antagonists_NNS
        tested_VBN differ_VB with_IN respect_NN to_TO this_DT binding_JJ loop_NN ._. Since_IN the_DT
        role_NN of_IN a_DT competitive_JJ antagonist_NN is_VBZ simply_RB to_TO block_VB the_DT
        binding_JJ of_IN agonists_NNS and_CC prevent_VB channel_NN opening_NN ,_, the_DT
        specific_JJ amino_JJ acids_NNS that_WDT interact_NN with_IN the_DT ligand_NN can_MD vary_VB
        for_IN different_JJ antagonists_NNS ._. This_DT is_VBZ less_RBR likely_JJ to_TO be_VB the_DT
        case_NN with_IN agonists_NNS since_IN they_PRP must_MD produce_VB a_DT conformational_NN
        change_NN in_IN the_DT protein_NN to_TO exert_VB their_PRP$ effects_NNS ._.
        Only_RB two_CD mutant_JJ receptors_NNS failed_VBD to_TO bind_NN [_NN
        3_CD H_NNP ]_NN granisetron_NN ;_: G_NNP 147_CD A_DT and_CC V_NNP 149_CD A_DT ._. G_NNP 147_CD is_VBZ the_DT conserved_JJ
        glycine_NN in_IN this_DT putative_JJ binding_JJ loop_NN ._. Chirara_NNP 
        et_CC ._. al_NN ._. have_VBP suggested_VBN that_IN the_DT
        highly_RB conserved_JJ nature_NN of_IN the_DT glycine_NN in_IN this_DT region_NN may_MD
        indicate_VB the_DT existence_NN of_IN a_DT loop_NN structure_NN consisting_VBG of_IN
        either_DT γ_NN or_CC a_DT loose_JJ three_CD residue-turn_JJ in_IN the_DT nAChR_NN [_NN 12_CD ]_NN
        ._. Either_CC of_IN these_DT turns_VBZ would_MD bring_VB the_DT two_CD putative_JJ
        β-strands_JJ together_RB such_JJ that_DT γL_NN 109_CD ,_, γY_NN 111_CD and_CC γS_NN 115_CD and_CC
        γY_NN 117_CD are_VBP all_DT on_IN the_DT same_JJ side_NN of_IN an_DT antiparallel_NN β-sheet_JJ ._.
        These_DT residues_NNS have_VBP been_VBN identified_VBN by_IN affinity_NN labeling_VBG ,_,
        site-directed_JJ mutagenesis_NNS or_CC cysteine_NN substitution_NN to_TO lie_VB
        on_IN the_DT same_JJ surface_NN ._. A_DT classic_JJ 2_CD -_: residue_NN β-turn_JJ would_MD place_VB
        these_DT residues_NNS on_IN opposite_JJ surfaces_VBZ [_NN 12_CD ]_NN ._. Substitution_NNP
        of_IN the_DT conserved_JJ glycine_NN by_IN alanine_NN may_MD disrupt_VB the_DT
        structure_NN of_IN this_DT region_NN and_CC prevent_VB assembly_NN or_CC expression_NN
        of_IN the_DT receptor_NN ._. The_DT recent_JJ determination_NN of_IN the_DT crystal_NN
        structure_NN of_IN an_DT AChBP_NNP supports_VBZ this_DT hypothesis_NNS ._. The_DT AChBP_NNP
        displays_VBZ a_DT large_JJ amount_NN of_IN homology_NN to_TO the_DT amino_JJ terminal_NN
        of_IN LGIC_NNP receptors_NNS and_CC thus_RB may_MD be_VB similar_JJ in_IN structure_NN [_NN 20_CD
        24_CD ]_NN ._. The_DT crystal_NN structure_NN of_IN this_DT protein_NN reveals_VBZ a_DT
        loose_JJ 3_CD residue_NN turn_NN incorporating_VBG the_DT conserved_JJ glycine_NN
        residue_NN [_NN 24_CD ]_NN ._. Homologous_NNP residues_NNS in_IN other_JJ LGIC_NNP subunits_NNS
        have_VBP also_RB been_VBN identified_VBN and_CC are_VBP shown_VBN in_IN Figure_NN 1_CD ._. The_DT
        residues_NNS identified_VBN in_IN this_DT study_NN as_IN altering_VBG binding_JJ
        affinity_NN of_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS would_MD also_RB be_VB present_JJ on_IN the_DT
        same_JJ surface_NN if_IN this_DT structure_NN is_VBZ present_JJ in_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ._. While_IN Y_NNP 140_CD lies_VBZ somewhat_RB outside_IN
        the_DT region_NN identified_VBN by_IN Chiara_NNP in_IN the_DT nAChR_NN (_( homologous_RB to_TO
        γN_NN 107_CD )_) ,_, γL_NN 109_CD and_CC γL_NN 119_CD are_VBP homologous_RB to_TO Y_NNP 142_CD and_CC Y_NNP 152_CD of_IN
        the_DT 5_CD -_: HT_NNP 
        3_CD AS_NNP R_NNP ._. The_DT ability_NN of_IN lerisetron_NN to_TO
        interact_NN with_IN both_DT Y_NNP 142_CD and_CC Y_NNP 152_CD also_RB supports_VBZ the_DT
        hypothesis_NNS that_IN these_DT two_CD amino_JJ acids_NNS are_VBP present_JJ in_IN a_DT loop_NN
        structure_NN since_IN the_DT eight_CD intervening_VBG residues_NNS would_MD
        position_VB Y_NNP 142_CD and_CC Y_NNP 152_CD too_RB far_RB apart_RB to_TO permit_VB them_PRP both_DT to_TO
        interact_NN with_IN a_DT single_JJ ligand_NN even_RB if_IN they_PRP were_VBD interacting_VBG
        with_IN functional_JJ groups_NNS on_IN opposite_JJ ends_NNS of_IN the_DT molecule_NN ._. A_DT
        loop_NN structure_NN would_MD bring_VB them_PRP into_IN closer_JJR proximity_NN and_CC
        permit_VB interaction_NN with_IN the_DT small_JJ molecule_NN lerisetron_NN ._.
        All_DT three_CD tyrosine_NN mutations_NNS were_VBD investigated_VBN using_VBG a_DT
        whole_JJ cell_NN patch_NN clamp_NN assay_NN to_TO determine_VB if_IN functional_JJ
        changes_NNS could_MD be_VB observed_VBN ._. Whole_JJ cell_NN responses_NNS could_MD not_RB
        be_VB obtained_VBN for_IN Y_NNP 140_CD A_DT or_CC Y_NNP 142_CD A_DT ,_, although_IN specific_JJ binding_JJ
        of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN was_VBD observed_VBN ._. These_DT data_NNS suggest_VBP that_IN ,_,
        while_IN the_DT receptors_NNS do_VBP assemble_VB and_CC are_VBP capable_JJ of_IN binding_JJ
        [_NN 3_CD H_NNP ]_NN granisetron_NN ,_, they_PRP are_VBP either_CC not_RB transported_VBN to_TO the_DT
        cell_NN surface_NN or_CC are_VBP non-responsive_JJ to_TO 5_CD -_: HT_NNP at_IN
        concentrations_NNS of_IN 1_CD mM_NN or_CC less_JJR ._.
        Y_NNP 152_CD A_DT does_VBZ produce_NN functional_JJ channels_NNS however_RB they_PRP
        display_VBP distinctly_RB altered_VBD response_NN kinetics_NNS when_WRB compared_VBN
        to_TO wildtype_NN receptors_NNS ._. Y_NNP 152_CD A_DT responses_NNS do_VBP not_RB show_VB the_DT
        rapid_JJ rise_NN times_NNS observed_VBD in_IN wt_NN receptors_NNS ._. The_DT extremely_RB
        slow_JJ rise_NN times_NNS observed_VBD for_IN Y_NNP 152_CD A_DT receptors_NNS may_MD indicate_VB a_DT
        change_NN in_IN rate_NN constants_NNS preceding_VBG channel_NN opening_NN ._. These_DT
        changes_NNS in_IN the_DT rate_NN constants_NNS for_IN either_DT agonist_NN binding_JJ or_CC
        channel_NN opening_NN also_RB produce_VB a_DT 140_CD fold_VB decrease_VB in_IN the_DT
        observed_VBN EC_NNP 
        50_CD for_IN 5_CD -_: HT_NNP activation_NN ._. The_DT slow_JJ rise_NN is_VBZ
        followed_VBN by_IN a_DT non-desensitizing_JJ phase_NN of_IN the_DT response_NN that_WDT
        is_VBZ dramatically_RB different_JJ from_IN the_DT fast_JJ desensitization_NN
        observed_VBD for_IN wt_NN 5_CD -_: HT_NNP 
        3_CD AS_NNP Rs_NNP ._. Lack_NN of_IN desensitization_NN could_MD
        result_VB from_IN either_DT a_DT stabilization_NN of_IN the_DT open_JJ state_NN of_IN the_DT
        channel_NN or_CC a_DT destabilization_NN of_IN the_DT desensitized_JJ state_NN ._.
        Mutations_NNP of_IN homologous_RB or_CC nearby_JJ residues_NNS in_IN both_DT the_DT
        nAChR_NN and_CC GABA_NNP 
        A_DT receptors_NNS have_VBP also_RB been_VBN demonstrated_VBN
        to_TO alter_VB the_DT agonist_NN response_NN ._. Mutation_NNP of_IN the_DT homologous_RB
        residue_NN in_IN the_DT GABA_NNP 
        A_DT receptor_NN γ-subunit_JJ (_( T_NN 142_CD )_) to_TO serine_NN
        altered_VBD the_DT efficacy_NN of_IN the_DT agonist_NN Flumazenil_NNP ,_, converting_VBG
        it_PRP to_TO a_DT partial_JJ agonist_NN [_NN 29_CD ]_NN ._. In_IN the_DT nAChR_NN ,_, mutation_NN of_IN
        mouse_NN and_CC rat_NN εP_NN 121_CD to_TO leucine_NN altered_VBD both_DT the_DT binding_JJ of_IN
        acetylcholine_NN and_CC the_DT stability_NN of_IN the_DT open_JJ state_NN of_IN the_DT
        channel_NN ._. εP_NN 121_CD is_VBZ homologous_RB to_TO P_NN 154_CD in_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN and_CC is_VBZ only_RB two_CD residues_NNS away_RB from_IN
        Y_NNP 152_CD ._. The_DT authors_NNS of_IN this_DT study_NN concluded_VBD that_IN this_DT portion_NN
        of_IN the_DT acetylcholine_NN binding_JJ site_NN was_VBD closely_RB linked_VBN to_TO the_DT
        channel_NN opening_VBG region_NN of_IN the_DT receptor_NN [_NN 30_CD ]_NN ._. It_PRP is_VBZ
        reasonable_JJ to_TO conclude_VB that_IN the_DT homologous_RB region_NN in_IN the_DT
        5_CD -_: HT_NNP 
        3_CD R_NN may_MD perform_VB a_DT similar_JJ function_NN ._. The_DT
        link_NN between_IN an_DT agonist_NN binding_JJ domain_NN and_CC a_DT conformational_NN
        change_NN leading_VBG to_TO channel_VB opening_NN is_VBZ not_RB unexpected_JJ since_IN
        the_DT two_CD must_MD obviously_RB be_VB linked_VBN ._. If_IN binding_VBG to_TO this_DT region_NN
        of_IN the_DT receptor_NN is_VBZ shown_VBN to_TO be_VB a_DT critical_JJ step_NN between_IN the_DT
        binding_JJ of_IN agonists_NNS and_CC the_DT opening_NN of_IN the_DT channel_NN ,_, further_JJ
        investigation_NN of_IN the_DT amino_JJ acids_NNS in_IN this_DT loop_NN may_MD provide_VB
        valuable_JJ clues_NNS to_TO molecular_JJ basis_NN of_IN this_DT process_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ data_NNS indicate_VBP an_DT important_JJ role_NN for_IN this_DT putative_JJ
        binding_JJ site_NN loop_NN in_IN the_DT interaction_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN with_IN different_JJ ligands_NNS and_CC
        illustrate_VBP the_DT difference_NN in_IN binding_JJ of_IN different_JJ
        structural_JJ classes_NNS of_IN ligands_NNS ._. Each_DT structural_JJ class_NN shows_VBZ
        different_JJ patterns_NNS of_IN interaction_NN with_IN amino_JJ acids_NNS in_IN this_DT
        region_NN of_IN the_DT receptor_NN ._. [_NN 3_CD H_NNP ]_NN granisetron_NN does_VBZ not_RB appear_VB to_TO
        interact_NN with_IN any_DT of_IN the_DT amino_JJ acids_NNS tested_VBN while_IN 
        d_SYM -_: tc_NN interacts_NNS with_IN only_RB Y_NNP 140_CD ,_, 
        m_NN CPBG_NNP and_CC 5_CD -_: HT_NNP with_IN Y_NNP 142_CD and_CC
        lerisetron_NN with_IN both_DT Y_NNP 142_CD and_CC Y_NNP 152_CD ._. Similar_JJ selective_JJ
        effects_NNS have_VBP been_VBN observed_VBN on_IN other_JJ residues_NNS including_VBG
        W_NNP 183_CD ,_, W_NNP 89_CD ,_, F_NN 107_CD and_CC E_NNP 106_CD among_IN others_NNS [_NN 20_CD 21_CD 25_CD 26_CD ]_NN ._. Our_PRP$
        data_NNS in_IN conjunction_NN with_IN those_DT of_IN other_JJ laboratories_NNS
        indicates_VBZ the_DT differences_NNS in_IN orientation_NN of_IN different_JJ
        ligands_NNS within_IN the_DT same_JJ binding_JJ cleft_NN ._. These_DT differences_NNS in_IN
        orientation_NN result_NN in_IN different_JJ amino_JJ acid_NN /_NN functional_JJ group_NN
        interactions_NNS ._. As_IN the_DT structural_JJ detail_NN of_IN these_DT
        interactions_NNS emerges_VBZ ,_, these_DT differences_NNS could_MD potentially_RB
        be_VB exploited_VBN to_TO produce_VB more_RBR potent_JJ and_CC specific_JJ ligands_NNS ._.
        For_IN example_NN construction_NN of_IN a_DT "_'' hybrid_JJ "_'' ligand_NN that_WDT combines_VBZ
        the_DT interactions_NNS of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN with_IN those_DT of_IN 
        d_SYM -_: tc_NN ,_, 5_CD -_: HT_NNP or_CC 
        m_NN CPBG_NNP could_MD produce_VB an_DT antagonist_NN
        with_IN increased_VBN affinity_NN due_JJ to_TO the_DT additional_JJ binding_JJ
        energy_NN of_IN these_DT interactions_NNS and_CC a_DT greater_JJR specificity_NN
        since_IN it_PRP would_MD utilize_VB more_RBR structural_JJ features_NNS of_IN the_DT
        binding_JJ site_NN ._.
        The_DT requirement_NN of_IN a_DT glycine_NN at_IN position_NN 147_CD and_CC the_DT
        ability_NN of_IN lerisetron_NN to_TO interact_NN with_IN both_DT Y_NNP 142_CD and_CC Y_NNP 152_CD
        also_RB support_NN the_DT hypothesis_NNS that_IN the_DT secondary_JJ structure_NN in_IN
        this_DT region_NN of_IN the_DT receptor_NN is_VBZ formed_VBN by_IN a_DT loop_NN structure_NN ._.
        If_IN the_DT loose_JJ 3_CD residue_NN turn_NN proposed_VBN by_IN Chiara_NNP 
        et_CC ._. al_NN ._. and_CC shown_VBN for_IN the_DT AChBP_NNP is_VBZ
        present_JJ in_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ,_, then_RB Y_NNP 140_CD ,_, Y_NNP 142_CD and_CC Y_NNP 152_CD would_MD be_VB
        present_JJ on_IN the_DT same_JJ side_NN of_IN the_DT sheet_NN and_CC all_DT three_CD would_MD
        be_VB capable_JJ of_IN extending_VBG into_IN the_DT binding_JJ site_NN ._. A_DT similar_JJ
        observation_NN has_VBZ been_VBN made_VBN for_IN the_DT nAChR_NN where_WRB γS_NN 111_CD ,_, γY_NN 117_CD ,_,
        γL_NN 119_CD ,_, δR_NN 113_CD and_CC δT_NN 119_CD of_IN the_DT mouse_NN nAChR_NN receptor_NN and_CC
        γL_NN 109_CD and_CC γY_NN 111_CD of_IN the_DT torpedo_VB nAChR_NN are_VBP all_DT thought_VBN to_TO be_VB
        present_JJ in_IN the_DT binding_JJ site_NN [_NN 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Materials_NNS
          [_NN 3_CD H_NNP ]_NN granisetron_NN was_VBD purchased_VBN from_IN New_NNP England_NNP
          Nuclear_NNP ,_, 5_CD -_: HT_NNP from_IN Spectrum_NNP ,_, and_CC 
          m_NN CPBG_NNP and_CC 
          d_SYM -_: tc_NN from_IN Research_NNP Biochemical_NNP
          International_NNP ._. Lerisetron_NNP was_VBD provided_VBN by_IN Dr_NNP ._. Karen_NNP
          Kirschbaum_NNP at_IN The_DT University_NNP of_IN Louisiana_NNP at_IN Monroe_NNP ,_,
          Monroe_NNP ,_, LA_NNP ._. All_DT other_JJ reagents_NNS were_VBD obtained_VBN from_IN
          commercial_JJ sources_NNS ._.
        
        
          Site_NNP directed_VBD mutagenesis_NNS
          Wild_NNP type_NN 5_CD -_: HT_NNP 
          3_CD AS_NNP mouse_NN receptor_NN cDNA_NN was_VBD obtained_VBN
          from_IN Dr_NNP ._. Michael_NNP White_NNP [_NN 20_CD ]_NN ._. Mutant_NNP receptors_NNS were_VBD
          constructed_VBN using_VBG either_CC the_DT Quick_NNP Change_NNP Mutagenesis_NNP kit_NN
          (_( Stratagene_NNP )_) or_CC the_DT Altered_NNP Sites_NNP Mutagenesis_NNP kit_NN
          (_( Promega_NNP )_) ._. All_DT mutations_NNS were_VBD confirmed_VBN by_IN commercial_JJ DNA_NNP
          sequencing_VBG ._.
        
        
          Cell_NNP culture_NN and_CC transfection_NN
          tsA_NN 201_CD cells_NNS ,_, a_DT derivative_NN of_IN HEK_NNP 293_CD cells_NNS ,_, were_VBD
          seeded_VBN at_IN a_DT density_NN of_IN 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN 100_CD mm_NN dish_NN ._. Cells_NNP
          were_VBD grown_VBN in_IN DMEM_NNP medium_NN containing_VBG 10_CD %_NN FBS_NNP ,_, 100_CD
          units_NNS /_NN ml_NN penicillin_NN /_NN streptomycin_NN for_IN nine_CD hours_NNS in_IN 5_CD %_NN CO_NNP 
          2_CD and_CC transfected_JJ with_IN 10_CD μg_NN mouse_NN
          5_CD -_: HT_NNP 
          3_CD AS_NNP R_NNP cDNA_NN per_IN 100_CD mm_NN dish_NN using_VBG the_DT
          calcium_NN phosphate_NN technique_NN (_( New_NNP Life_NNP Technologies_NNPS ,_, NY_NNP )_) ._.
          Media_NNP was_VBD changed_VBN 12_CD -_: 14_CD hrs_NNS after_IN transfection_NN ._. The_DT cells_NNS
          were_VBD allowed_VBN to_TO grow_VB for_IN another_DT 24_CD hours_NNS and_CC then_RB
          harvested_VBN ._.
          For_IN whole_JJ cell_NN patch_NN clamp_NN experiments_NNS ,_, tsA_NN 201_CD cells_NNS
          were_VBD seeded_VBN to_TO a_DT density_NN of_IN 0_CD ._. 25_CD ×_NN 10_CD 6_CD cells_NNS /_NN 60_CD mm_NN dish_NN ._.
          Cells_NNP were_VBD grown_VBN in_IN DMEM_NNP culture_NN medium_NN containing_VBG 10_CD %_NN
          FBS_NNP and_CC 100_CD units_NNS /_NN ml_NN penicillin_NN /_NN streptomycin_NN for_IN 12_CD hours_NNS
          prior_RB to_TO transfection_NN ._. Transfections_NNP were_VBD performed_VBN using_VBG
          Superfect_NNP Transfection_NNP Reagent_NNP (_( Qiagen_NNP ,_, CA_NNP )_) ._. Ten_CD μg_NN of_IN
          cDNA_NN were_VBD mixed_VBN with_IN DMEM_NNP medium_NN containing_VBG no_DT serum_NN or_CC
          antibiotics_NNS in_IN a_DT volume_NN of_IN 150_CD μl_NN ._. Twenty_CD μl_NN of_IN Superfect_NNP
          reagent_NN were_VBD then_RB added_VBN and_CC the_DT mixture_NN incubated_JJ at_IN room_NN
          temperature_NN for_IN 15_CD min_NN ._. The_DT reaction_NN was_VBD terminated_VBN by_IN
          adding_VBG 1_CD ml_NN of_IN DMEM_NNP medium_NN containing_VBG 10_CD %_NN FBS_NNP and_CC 100_CD
          units_NNS /_NN ml_NN penicillin_NN /_NN streptomycin_NN and_CC the_DT entire_JJ mixture_NN
          added_VBD to_TO cells_NNS in_IN the_DT 60_CD mm_NN dish_NN ._. Cells_NNP were_VBD exposed_VBN to_TO
          Superfect_NNP Reagent_NNP for_IN 3_CD hours_NNS ._. At_IN that_DT time_NN ,_, the_DT reagent_NN
          was_VBD replaced_VBN with_IN DMEM_NNP medium_NN containing_VBG 10_CD %_NN FBS_NNP and_CC 100_CD
          units_NNS /_NN ml_NN penicillin_NN /_NN streptomycin_NN and_CC incubated_JJ for_IN an_DT
          additional_JJ 24_CD hours_NNS prior_RB to_TO use_VB ._.
        
        
          Binding_NNP assays_NNS
          Transfected_NNP cells_NNS were_VBD scraped_JJ from_IN the_DT dishes_NNS ,_, washed_VBD
          twice_RB with_IN Dulbecco_NNP 's_POS PBS_NNP (_( New_NNP Life_NNP Technologies_NNPS ,_, NY_NNP )_) ,_,
          then_RB resuspended_JJ in_IN 1_CD ._. 0_CD ml_NN ice_NN cold_JJ PBS_NNP /_NN 100_CD mm_NN dish_NN ._.
          Cells_NNP were_VBD either_CC used_VBN fresh_JJ or_CC frozen_VBN at_IN this_DT step_NN until_IN
          needed_VBN ._. Immediately_RB prior_RB to_TO use_VB ,_, cells_NNS were_VBD homogenized_JJ
          on_IN ice_NN in_IN PBS_NNP using_VBG a_DT glass_NN tissue_NN homogenizer_NN then_RB
          centrifuged_JJ at_IN 35_CD 000_CD ×_NN g_SYM for_IN 30_CD minutes_NNS in_IN a_DT Beckman_NNP
          JA_NNP 20_CD rotor_NN (_( 4_CD °_NN C_NNP )_) ._. Membranes_NNP were_VBD washed_VBN once_RB more_JJR with_IN
          PBS_NNP at_IN 4_CD °_NN C_NNP then_RB resuspended_JJ in_IN 1_CD ml_NN PBS_NNP /_NN 100_CD mm_NN dish_NN ._.
          Protein_NNP content_NN was_VBD determined_VBN using_VBG a_DT Lowry_NNP assay_NN
          (_( Sigma_NNP ._. Diagnostics_NNPS ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. Membranes_NNP were_VBD
          initially_RB prepared_VBN and_CC B_NNP 
          max_NN and_CC K_NNP 
          d_SYM values_NNS determined_VBN in_IN the_DT presence_NN
          and_CC absence_NN of_IN a_DT cocktail_NN of_IN protease_NN inhibitors_NNS
          (_( Complete_JJ Protease_NNP Inhibitor_NNP Cocktail_NNP ,_, Roche_NNP Diagnostics_NNPS ,_,
          Mannheim_NNP Germany_NNP )_) ._. No_DT change_NN in_IN B_NNP 
          max_NN was_VBD observed_VBN as_IN a_DT result_NN of_IN
          omitting_VBG the_DT protease_NN inhibitor_NN (_( B_NNP 
          max_NN (_( +_NN protease_NN inhibitor_NN )_) =_SYM 3_CD ._. 1_CD ±_NN 0_CD ._. 11_CD
          pmoles_NNS /_NN mg_NN protein_NN vs_NNS B_NNP 
          max_NN (_( -_: protease_NN inhibitor_NN )_) =_SYM 3_CD ._. 2_CD ±_NN
          0_CD ._. 13_CD pmoles_NNS /_NN mg_NN protein_NN ._. )_) hence_RB all_DT assays_NNS were_VBD performed_VBN
          in_IN the_DT absence_NN of_IN the_DT cocktail_NN ._. Binding_NNP assays_NNS were_VBD
          performed_VBN in_IN PBS_NNP ._.
          For_IN K_NNP 
          d_SYM determinations_NNS ,_, 100_CD μl_NN of_IN homogenate_NN
          was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 1_CD hour_NN with_IN varying_VBG
          concentrations_NNS of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN (_( NEN_NNP ,_, MA_NNP )_) ._. Specific_JJ
          binding_JJ of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN was_VBD determined_VBN as_IN the_DT bound_VBN [_NN
          3_CD H_NNP ]_NN granisetron_NN not_RB displaced_VBN by_IN a_DT saturating_VBG
          concentration_NN of_IN a_DT competing_VBG ligand_NN ._. K_NNP 
          d_SYM values_NNS were_VBD determined_VBN by_IN fitting_JJ
          the_DT binding_JJ data_NN to_TO the_DT following_VBG equation_NN using_VBG Graphpad_NNP
          PRISM_NNP (_( San_NNP Diego_NNP CA_NNP )_) :_: B_NN =_SYM B_NNP 
          max_NN [_NN L_NNP ]_NN n_NN /_NN (_( [_NN L_NNP ]_NN n_NN +_NN K_NNP n_NN )_) ,_, where_WRB B_NNP is_VBZ
          bound_VBN ligand_NN ,_, B_NNP 
          max_NN is_VBZ the_DT maximum_NN binding_JJ at_IN
          equilibrium_NN L_NNP is_VBZ the_DT free_JJ ligand_NN concentration_NN and_CC n_NN is_VBZ
          the_DT Hill_NNP coefficient_NN ._.
          K_NNP 
          i_NNP determinations_NNS ,_, 100_CD μl_NN of_IN homogenate_NN
          was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 2_CD hours_NNS with_IN varying_VBG
          concentrations_NNS of_IN inhibitor_NN and_CC [_NN 3_CD H_NNP ]_NN granisetron_NN (_( NEN_NNP ,_,
          MA_NNP )_) ._. Binding_NNP was_VBD terminated_VBN by_IN rapid_JJ filtration_NN onto_IN a_DT
          GF_NNP /_NN B_NNP filters_NNS ._. The_DT IC_NNP 
          50_CD values_NNS were_VBD calculated_VBN by_IN fitting_JJ
          the_DT data_NNS to_TO the_DT following_VBG equation_NN using_VBG Graphpad_NNP PRISM_NNP
          (_( San_NNP Diego_NNP CA_NNP )_) :_: θ_NN =_SYM 1_CD /_NN (_( 1_CD +_NN (_( L_NNP /_NN IC_NNP 
          50_CD )_) )_) ,_, where_WRB θ_NN is_VBZ the_DT fractional_JJ
          amount_NN of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN bound_VBN in_IN the_DT presence_NN of_IN
          inhibitor_NN at_IN concentration_NN L_NNP as_IN compared_VBN to_TO the_DT amount_NN of_IN
          [_NN 3_CD H_NNP ]_NN granisetron_NN bound_VBN in_IN the_DT absence_NN of_IN inhibitor_NN ._. IC_NNP 
          50_CD is_VBZ the_DT concentration_NN at_IN which_WDT θ_NN =_SYM
          0_CD ._. 5_CD ._. The_DT K_NNP 
          i_NNP is_VBZ calculated_VBN from_IN the_DT IC_NNP 
          50_CD value_NN using_VBG the_DT Cheng-_NNP Prusoff_NNP
          equation_NN ._.
        
        
          Electrophysiological_NNP Recordings_NNP
          Transfected_NNP cells_NNS were_VBD transferred_VBN to_TO a_DT recording_NN
          chamber_NN containing_VBG extracellular_NN solution_NN (_( 140_CD mM_NN NaCl_NNP ,_,
          1_CD ._. 7_CD mM_NN MgCl_NNP 
          2_CD ,_, 5_CD mM_NN KCl_NNP ,_, 1_CD ._. 8_CD mM_NN CaCl_NNP 
          2_CD ,_, 25_CD mM_NN HEPES_NNP pH_NN 7_CD ._. 4_LS )_) ._. Patch_NNP
          electrodes_NNS of_IN resistance_NN 2_CD ._. 5_CD -_: 3_CD ._. 0_CD MΩ_NNP were_VBD filled_VBN with_IN
          filtered_VBN intracellular_NN solution_NN containing_VBG 145_CD mM_NN KCl_NNP ,_, 2_CD
          mM_NN MgCl_NNP 
          2_CD ,_, 1_CD mM_NN EGTA_NNP ,_, 25_CD mM_NN HEPES_NNP (_( pH_NN 7_CD ._. 4_LS )_) ._.
          Cells_NNP were_VBD clamped_VBN in_IN whole_JJ cell_NN configuration_NN at_IN a_DT
          holding_VBG potential_NN of_IN -_: 60_CD mV_NN ._. A_DT continuous_JJ extracellular_NN
          solution_NN flow_NN (_( 0_CD ._. 8_CD ml_NN /_NN min_NN )_) was_VBD maintained_VBN throughout_IN the_DT
          recording_NN procedure_NN ._. 5_LS -_: HT_NNP was_VBD dissolved_VBN in_IN extracellular_NN
          solution_NN and_CC delivered_VBN to_TO cells_NNS using_VBG a_DT rapid_JJ perfusion_NN
          system_NN (_( Warner_NNP Instruments_NNP ,_, Hamden_NNP ,_, CT_NNP )_) at_IN a_DT rate_NN
          matching_VBG the_DT extracellular_NN solution_NN flow_NN rate_NN ._. The_DT drug_NN
          perfusions_NNS lasted_VBD for_IN a_DT period_NN varying_VBG from_IN 4_CD to_TO 8_CD
          seconds_NNS ._. Currents_NNP elicited_JJ by_IN agonist_NN application_NN were_VBD
          measured_VBN using_VBG an_DT Axopatch_NNP 200_CD B_NNP amplifier_NN (_( Foster_NNP City_NNP ,_,
          CA_NNP )_) ._. The_DT data_NNS were_VBD plotted_VBD and_CC analyzed_VBN by_IN non-linear_JJ
          curve_NN fitting_JJ (_( Graphpad_NNP PRISM_NNP ,_, San_NNP Diego_NNP CA_NNP )_) according_VBG to_TO
          the_DT following_JJ equation_NN :_: I_PRP =_SYM 1_CD /_NN (_( 1_CD +_NN (_( EC_NNP 
          50_CD /_NN [_NN C_NNP ]_NN )_) n_NN )_) ,_, where_WRB is_VBZ the_DT normalized_JJ
          current_NN at_IN 5_CD -_: HT_NNP concentration_NN [_NN C_NNP ]_NN ,_, EC_NNP 
          50_CD is_VBZ the_DT concentration_NN of_IN 5_CD -_: HT_NNP needed_VBD
          to_TO obtain_VB half_JJ maximal_NN activation_NN and_CC n_NN is_VBZ the_DT apparent_JJ
          Hill_NNP coefficient_NN ._.
        
      
    
  
